Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

Share Price is delayed by 15 minutes
Get Live Data
36.40    0.00 (0.00%)
Bid:
36.40
Ask:
36.90
Spread: 0.50 (1.374%)
Market Cap: £26.37m
NCYT Live PriceLast checked at - London Stock Exchange

Intraday Novacyt Share Chart

AGM voting

3 Jun 2024 07:00

RNS Number : 7294Q
Novacyt S.A.
03 June 2024
 

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

AGM voting

 

Paris, France, and Eastleigh and Manchester, UK - 3 June 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, will be holding its annual general meeting ("AGM") exclusively as an open online meeting at 2pm CEST/1pm BST on Wednesday, 26 June 2024. As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary resolutions. All materials can be found at www.novacyt.com/investors.

 

Shareholders are strongly encouraged to submit their votes in advance, in accordance with the instructions in the Notice of the AGM.

 

Under French law, for the AGM and EGM meetings to be quorate at the first attempt, shareholders representing at least 20% of the share capital and voting rights, on ordinary resolutions, and 25% of the share capital and voting rights, on extraordinary resolutions, must be present, represented or have voted in advance under the conditions set out below.

 

Shareholders can vote in advance of the AGM by:

 

• Downloading a copy of the proxy voting form from the website www.novacyt.com/investors, completing it and returning it together with evidence of their shareholding which must be in the form of a share certificate (attestation), either by post to the following address: 6 avenue de Provence 75452 Paris Cedex 09, or via email to the following address: serviceproxy@cic.fr, or investor.relations@novacyt.com, no later than 24 June 2024 inclusive.

• Voting on-line using the Votaccess portal http://www.actionnaire.cic-marketsolutions.eu if securities held on Euronext Growth are registered with any of the following banks: CIC, Natixis, Société Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank, Bank of New York or JP Morgan. The Votaccess portal will be open from 3 June 2024 to 25 June 2023 2pm BST/3pm CEST.

• Voting on-line via a broker, nominee, bank or authorised intermediary. Many intermediaries in the UK such as Hargreaves Lansdown are now using the Broadridge ProxyVote on-line voting portal.

 

Shareholders can register for the AGM and access the online meeting by visiting https://reg.lumiengage.com/novacyt-sa-agm-2024/novacytagm2024/Site/Register. Registrations must be accompanied by formal evidence of shareholding.

 

Following registration approval, shareholders will be able to virtually attend the AGM and vote online during the meeting if they wish, providing formal evidence of holding has been provided prior to the meeting.

 

Shareholders who have already voted (through a proxy, via their broker, nominee, bank, authorised intermediary, Votaccess portal or Broadridge ProxyVote) will be allowed to attend the AGM but will not be able to vote twice.

 

Following the meeting, a recording of the AGM will be available on the Company's website at www.novacyt.com/investors.

 

Contacts

 

Novacyt SA

https://novacyt.com/investors

Lyn Rees, Chief Executive Officer

 Via Walbrook PR

Steve Gibson, Chief Financial Officer 

 

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

+44 (0)20 3470 0470

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

Deutsche Numis (Joint Broker)

+44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Michael Palser

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

 +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)

Stephanie Cuthbert / Paul McManus /

Phillip Marriage / Alice Woodings

+44 (0)20 7933 8780 or novacyt@walbrookpr.com

+44 (0)7796 794 663 / +44 (0)7980 541 893

 +44 (0)7867 984 082 / +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

 

The Company is divided into three business segments:

 

Clinical

Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:

· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests

· Precision Medicine: DPYD genotyping assay

· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

 

Instrumentation

Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

· Ranger® Technology: automated DNA sample preparation and target enrichment technology

· MyGo: real-time quantitative PCR (qPCR) instruments

 

Research Use Only 

Range of services for the life sciences industry:

· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry

· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

 

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMSDAFMFELSEFI
Date   Source Headline
10th Jun 20267:00 amRNSAGM Voting
1st Jun 20262:45 pmRNSLiquidity Agreement Monthly Update and TVR
1st Jun 20269:45 amRNSOperational Update
22nd May 20267:00 amRNSNotice of AGM
19th May 20267:00 amRNSLaunch of Yourgene® Insight DPYD assay
7th May 202610:00 amRNSDirectorate change
5th May 20262:00 pmRNSLiquidity Agreement Monthly Update and TVR
30th Apr 20267:00 amRNSFull Year 2025 results
8th Apr 20267:00 amRNSNotice of Results and Investor Presentation
1st Apr 202611:45 amRNSLiquidity Agreement Monthly Update and TVR
30th Mar 20263:00 pmRNSDirector/PDMR Shareholding
20th Mar 20267:00 amRNSResult of Preferential Subscription Rights Issue
2nd Mar 20263:30 pmRNSLiquidity Agreement Monthly Update and TVR
2nd Mar 20267:02 amRNSPreferential Subscription Rights Issue
2nd Mar 20267:00 amRNSCompletion of Acquisition
23rd Feb 20267:00 amRNSAcquisition of Southern Cross Diagnostics
2nd Feb 20263:45 pmRNSLiquidity Agreement Monthly Update and TVR
27th Jan 20267:00 amRNSNIPT Tender Award
21st Jan 20267:00 amRNSFull year trading update
2nd Jan 20261:30 pmRNSLiquidity Agreement Monthly Update and TVR
1st Dec 202512:00 pmRNSLiquidity Agreement Monthly Update and TVR
3rd Nov 20252:30 pmRNSLiquidity Agreement Monthly Update and TVR
22nd Oct 20257:00 amRNSStrategy update & notice of investor presentation
1st Oct 20254:00 pmRNSLiquidity Agreement Monthly Update and TVR
30th Sep 20257:00 amRNS2025 Interim results
18th Sep 20257:00 amRNSNotice of Results
15th Sep 20257:00 amRNSAppointment of Joint Corporate Broker
12th Sep 202510:00 amRNSResolution re. Lab 21 HSE Prosecution
1st Sep 20251:45 pmRNSLiquidity Agreement Monthly Update and TVR
1st Aug 20254:02 pmRNSLiquidity Agreement Monthly Update & TVR
29th Jul 20257:00 amRNSHalf-year trading update
15th Jul 20257:00 amRNSLaunch of LightBench® Discover
1st Jul 20251:45 pmRNSLiquidity Agreement Monthly Update and TVR
20th Jun 20257:00 amRNSResult of AGM
16th Jun 20257:00 amRNSPublication of Annual Report
2nd Jun 202511:30 amRNSLiquidity Agreement and Total Voting Rights
28th May 20257:00 amRNSAGM Voting
12th May 20257:00 amRNSNotice of AGM
2nd May 202512:30 pmRNSLiquidity Agreement Monthly Update and TVR
30th Apr 20257:00 amRNSFull Year 2024 Results
22nd Apr 20257:00 amRNSNotice of Results
1st Apr 202511:45 amRNSLiquidity Agreement and Total Voting Rights
18th Mar 20254:15 pmRNSUpdate re. Lab 21 HSE Prosecution
3rd Mar 20253:00 pmRNSLiquidity Agreement and Total Voting Rights
20th Feb 20257:00 amRNSIVDR accreditation for Yourgene QST*R Base assay
3rd Feb 20252:30 pmRNSLiquidity Agreement and Total Voting Rights
30th Jan 20257:00 amRNSFull year trading update
21st Jan 20253:30 pmRNSStatement re. HSE Prosecution
2nd Jan 20253:15 pmRNSLiquidity Agreement Monthly Update and TVR
10th Dec 20247:00 amRNSChange of Registered Office

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.